Cardiovascular outcomes of type 2 diabetic patients treated with DPP‑4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice | Scientific Reports

This retrospective cohort study analyzed electronic health records from UK primary care to compare cardiovascular outcomes in type 2 diabetic patients adding DPP-4 inhibitors to metformin versus those adding sulphonylureas. The research found that the incidence of major adverse cardiovascular events (MACE) and all-cause mortality was statistically similar between the two treatment groups, even after adjusting for various comorbidities. While a potential protective effect was observed for DPP-4 inhibitors in elderly patients with low BMI, the overall data suggests that cardiovascular prognosis should not be the deciding factor when choosing between these two add-on therapies.